PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Kukjeon (formerly Kukjeon Pharm), once centered on active pharmaceutical ingredients, turned operating profitable in the first half of 2026 as its precision chemical materials business for semiconductors and displays expanded.
Full-year 2025 operating profit was negative (-KRW 2.58 billion), but the company posted consecutive operating profits in Q1 2026 (+KRW 2.66 billion) and Q2 2026 (+KRW 1.50 billion).
The share of electronic/precision chemical materials revenue has risen from roughly 6% in full-year 2024 to about 9.25% in the first half of 2026.
The debt ratio declined from 131.0% in 2023 to 86.9% in 2025, indicating an improved balance sheet.
Phase 1 of the oral Alzheimer's drug candidate 'NuCerin,' co-developed with Chaperone, was completed in September 2026 with the clinical study report received.
Quarterly net income attributable to owners has shown large swings independent of operating profit, reflecting significant non-operating items.
Kukjeon was founded in 1995 and listed on KOSDAQ in 2020, and in April 2026 the company formally changed its name from Kukjeon Pharm to Kukjeon to signal its expanded business scope.
The company operates two main segments: pharmaceuticals (synthesis, import/distribution, and sale of active pharmaceutical ingredients) and materials (OLED, next-generation display, AI semiconductor packaging, and automotive-grade advanced materials).
The pharmaceutical segment supplies drugmakers and API distributors and has historically handled ingredients across cardiovascular, digestive, urogenital, and hormone/metabolic therapeutic categories.
The vast majority of revenue still comes from APIs, but the materials business has been scaling up quickly since the company completed an electronic materials plant in Eumseong, North Chungcheong Province in August 2023.
The materials segment is commercializing high-purity additives for HBM (High Bandwidth Memory) process applications and OLED emitting-material intermediates, and it has passed a qualification review on a global semiconductor maker's HBM production line to enter that supply chain.
On the pipeline side, the company holds domestic rights to 'NuCerin,' an oral Alzheimer's drug candidate in-licensed from Chaperone, and it also manufactures and supplies the key API for Chaperone's atopic dermatitis candidate 'NuGel,' which is in U.S. Phase 2 trials.
Ownership is concentrated, with CEO Jong-Ho Hong and related parties holding a majority stake, supporting management stability.
The company also broadened its registered business purpose from 'semiconductor materials manufacturing and sales' to 'precision chemical materials manufacturing and sales,' extending its reach beyond semiconductors into a wider range of specialty chemical materials.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩33.3B | -₩800M | −2.4% |
| 2025Q3 | ₩29.2B | -₩2B | −7.0% |
| 2025Q4 | ₩30.2B | ₩100M | 0.4% |
| 2026Q1 | ₩34.7B | ₩2.7B | 7.7% |
| 2026Q2 | ₩40.5B | ₩1.5B | 3.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩103.7B | ₩3.5B | ₩8.9B | 3.4% | 9.8% | 112.4% |
| 2023 | ₩122B | ₩6.5B | ₩4.8B | 5.3% | 5.0% | 131.0% |
| 2024 | ₩136.5B | ₩400M | ₩1.7B | 0.3% | 1.8% | 117.7% |
| 2025 | ₩131B | -₩2.6B | -₩4.3B | −2.0% | −4.5% | 86.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
In 2025, consolidated revenue was KRW 131.04 billion, a slight decline from KRW 136.47 billion in 2024, while operating profit swung to a loss of KRW 2.58 billion from a profit of KRW 0.37 billion in 2024.
Net income attributable to owners also turned negative at -KRW 4.30 billion versus +KRW 1.74 billion the prior year.
This reflects increased operating expenses from preemptive investment in building a dedicated electronic materials production line and proprietary technology, which carries the character of a temporary cost increase tied to the materials business expansion.
Looking at the quarterly trajectory, operating loss bottomed at -KRW 2.03 billion in Q3 2025 before turning to a profit of +KRW 0.14 billion in Q4 2025, and the company extended two consecutive quarters of operating profit into 2026 with +KRW 2.66 billion in Q1 and +KRW 1.50 billion in Q2.
Net income attributable to owners, however, diverged from the operating trend: Q1 2026, the quarter with the largest operating profit, actually posted a net loss of -KRW 2.66 billion, while Q2 2026 posted net income of +KRW 6.11 billion, exceeding the operating profit for that quarter.
This suggests non-operating items such as derivative valuation gains/losses and fair-value changes related to convertible bonds and bonds with warrants are driving much of the quarter-to-quarter volatility in net income.
On the balance sheet, the debt ratio fell sharply from 112.4% in 2022 and 131.0% in 2023 to 117.7% in 2024 and 86.9% in 2025, while operating cash flow stayed positive for two straight years at KRW 10.04 billion in 2024 and KRW 10.61 billion in 2025, a reversal from the negative cash flow seen in 2022-2023.
Revenue itself grew steadily from KRW 103.7 billion in 2022 to KRW 122.0 billion in 2023 and KRW 136.5 billion in 2024 before dipping slightly in 2025, which appears to reflect a combination of softer API-side demand and the timing of materials-segment revenue recognition.
The API industry serves domestic generic and finished-drug manufacturers and is a mature sector where quality-control capability and price competitiveness are the key variables.
Kukjeon has reportedly handled roughly 350 API items and maintains supply relationships across cardiovascular, digestive and other therapeutic categories.
By contrast, the HBM and OLED-related precision chemical materials market the company has entered is a growth area driven by the spread of AI semiconductors and rising high-bandwidth memory demand, and it requires high-purity, ultra-precision quality control where pharmaceutical GMP know-how can potentially be applied.
However, this market is already occupied by large specialty chemical incumbents in many product categories, so a later entrant such as Kukjeon must build share by passing customer qualification one product at a time.
The company has stated that it passed a qualification review on a global semiconductor maker's HBM production line to enter that supply chain, which, while still an early stage, represents a secured sales channel.
The pharmaceutical segment is exposed to a slowdown in the domestic generic drug market, while the materials segment is tied to the semiconductor and display industry cycle, meaning the two business lines can be driven by different factors.
Overall, the company is pursuing a dual-track strategy of funding new growth businesses with cash flow from its established pharmaceutical operations.
The company has set targets of KRW 10 billion in materials-segment revenue for 2026 and KRW 50 billion by 2027, with a mid-term company-wide revenue target of KRW 200 billion by 2027.
The rise in the electronic materials revenue share to 9.25% in the first half of 2026 can serve as one gauge of progress toward that goal. The pace of commercialization expansion in HBM and AI semiconductor packaging materials is cited as a key variable for the speed of future business diversification.
On the pipeline side, Phase 1 of NuCerin, co-developed with Chaperone, was completed in September 2026 with the clinical study report received, showing no adverse events and confirming safety; whether the program advances into Phase 2 and pursues global licensing remains a point to watch.
Overseas rights are held by Chaperone, so Kukjeon's structure allows it to benefit from any pipeline value appreciation through its domestic license and its role supplying the API.
Balance sheet improvement also appears to be an ongoing trend, and reduced interest expense from debt repayment could further contribute to earnings in the second half and beyond.
That said, because the materials segment's operating profit or loss is not disclosed separately, it is not yet clearly confirmed how much that segment specifically contributed to the company-wide swing to operating profit.
The current share price trades at a modest premium to the company's net asset value.
In past periods when the company was profitable, its price-to-earnings multiple has historically ranged broadly from around 50 times to over 90 times, so given the volatility of earnings, care is warranted in interpreting such multiples.
Looking at the most recent four quarters, operating profit has shown a trend toward turning positive, while net income attributable to owners has swung between losses and gains due to quarterly non-operating items, warranting attention to both the quality and sustainability of earnings.
On dividends, the company has effectively maintained a no-dividend policy in recent years, which is low relative to peer averages in the pharmaceutical and materials sectors.
Because the valuation structure simultaneously reflects the stable cash flow of the API business and growth expectations for the materials business, how the earnings contribution of each segment becomes distinguishable going forward could be a basis for any future re-rating.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The share of electronic materials revenue has risen from about 6% in 2024 to 9.25% in the first half of 2026, reflecting ongoing business diversification.
The fact that a high-purity additive for HBM processes passed a global semiconductor maker's line qualification and entered the supply chain can be viewed as an early growth driver. The company has set materials-segment revenue targets of KRW 10 billion for 2026 and KRW 50 billion for 2027.
The debt ratio fell sharply from 131.0% in 2023 to 86.9% in 2025, and operating cash flow was positive in both 2024 and 2025. Interest expense burden also appears to be declining through debt repayment.
The company posted operating profit in both Q1 and Q2 of 2026, suggesting its earnings structure is improving alongside the balance sheet.
Phase 1 of NuCerin, the oral Alzheimer's drug candidate co-developed with Chaperone, was completed in September 2026 with the clinical study report received. The trial confirmed safety, with no serious adverse events over seven days of oral dosing.
Kukjeon holds domestic rights and also supplies the key API for Chaperone's other pipeline asset NuGel, giving it an indirect structure to benefit from any increase in pipeline value.
In Q1 2026, operating profit exceeded KRW 2.6 billion yet net income attributable to owners posted a loss of KRW 2.66 billion, while Q2 saw net income of KRW 6.11 billion exceed the quarter's operating profit.
This shows non-operating items such as derivative and convertible-bond fair-value changes are swinging quarterly results considerably, and improvement in operating performance may not directly translate into improved net income.
Because the electronic materials segment's operating profit or loss is not disclosed separately, it is difficult for outside observers to confirm specifically how much that segment contributed to the company-wide swing to operating profit.
The 2025 operating loss was attributed to rising costs from preemptive materials-segment investment, and the pace at which that investment converts into realized returns warrants ongoing monitoring.
API revenue still accounts for nearly 90% of the total, so the materials business's actual contribution remains limited for now.
Consolidated revenue in 2025 was KRW 131.0 billion, a slight decline from KRW 136.5 billion the prior year, marking a break from the steady revenue growth seen from 2022 through 2024.
The API industry is a mature, price-competitive market, and continued softness in downstream generic demand could pressure the cash-generating capacity of the core business. With the materials business still accounting for under 10% of revenue, it is not easy for it to offset an API-segment slowdown in the short term.
The company has a history of raising funds through zero-coupon convertible bonds and bonds with warrants. If these mezzanine securities are converted or exercised in the future, the share count could increase, diluting per-share metrics.
While a high related-party ownership stake supports management stability, how any outstanding mezzanine volume is absorbed could be a variable for share supply and demand.
While NuCerin's Phase 1 trial confirmed safety, this stage does not establish efficacy and does not guarantee success in Phase 2 or Phase 3. Drug development carries the characteristic that both cost and failure probability tend to rise as clinical stages progress.
Because Chaperone holds the overseas rights, whether and on what terms any global licensing deal is concluded remains an uncertainty.
The materials business is linked to the capital spending and demand cycles of downstream industries such as AI semiconductors, HBM, and OLED. An early supply structure based on passing a specific customer's line qualification carries a risk of customer concentration until further diversification is achieved.
If the semiconductor or display industry slows, the pace of the materials business expansion could lag the company's plans.
Kukjeon's Q3 2026 quarterly report should be checked to see whether the operating profit streak extends to a third consecutive quarter and whether the materials segment's revenue share continues to rise.
Watch for disclosures or announcements regarding whether Chaperone advances NuCerin into Phase 2 trials or pursues a global licensing agreement.
Check whether the company secures additional customers or commercializes new products in HBM/OLED materials, and whether the materials segment's operating profit or loss is eventually disclosed separately.
Monitor any conversion or exercise requests on previously issued convertible bonds or bonds with warrants, and their size, to gauge potential share dilution.
Kukjeon is attempting a business transformation by adding a precision chemical materials business for semiconductors and displays on top of its stable core API operations.
The 2025 operating loss is explained by a temporary rise in costs from preemptive investment in the materials business, and signs of a turnaround have emerged with two consecutive quarters of operating profit in Q1 and Q2 2026.
However, net income attributable to owners has swung widely from quarter to quarter due to non-operating items, so it is important to view operating performance improvement separately from the net income trend.
Balance sheet improvement, including a declining debt ratio and a return to positive operating cash flow, is a clearly confirmed positive change. The drug pipeline has achieved an early milestone in confirming Phase 1 safety, but multiple stages remain before efficacy can be proven and commercialization achieved.
With the materials business still accounting for under 10% of revenue, it appears more time will be needed before its contribution to overall results becomes substantial, and investors may wish to track both the quarterly materials-segment revenue trend and the drivers behind swings in non-operating income items.
Report written 2026-10-03 · Data as of 2026-10-02
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.